Split (1)

train · 15.7k rows

code stringlengths 4 12	description stringlengths 2 264	codetype stringclasses 8 values	context stringlengths 160 15.5k
85999	HC EOSINOPHIL COUNT	HCPCS	It contains detailed descriptions of each procedure and any associated equipment costs and facility fees that may be involved with performing said procedure/treatment on a patient at an institution like yours! - HCPCS (Healthcare Common Procedure Coding System) – Another widely-used coding system that provides more specific information about individual services performed by healthcare professionals such as nurses or physicians who work within hospitals/clinics across America today! Below are the pathology codes that billing companies use: Field Code Range Anatomic Pathology 88000 – 88099 Hematology and Coagulation 85002 – 85999 Clinical Pathology Consultation 80500 – 80502 Surgical Pathology 88300 – 88399 Urinalysis 81000 – 81099 Molecular Pathology 81200 – 81479 Drug Testing 80100 – 80104 Chemistry 82000 – 84999 Cytopathology 88104 – 88199 Microbiology 87001 – 87999 Here are the top ICD-10 codes for pathology coding – - ICD-10-CM Code K29.50 – Medical ailments related to gastritis - ICD-10-CM Code K20.8 – Medical diagnosis of the allergic inflammatory condition in the esophagus - ICD-10-CM Code N20.1 – Code for kidney stones - ICD-10-CM Code C50.911 – Code that helps specify Breast cancer in women EMR System in Pathology Billing An EMR system is software that hospitals to manage patient records, including their medical history. Many doctors also use it to bill their patients, and it can be an essential tool for the medical billing industry. EMR is also known as Electronic Health Record (EHR) system.
80500	Lab pathology consultation	HCPCS	It contains detailed descriptions of each procedure and any associated equipment costs and facility fees that may be involved with performing said procedure/treatment on a patient at an institution like yours! - HCPCS (Healthcare Common Procedure Coding System) – Another widely-used coding system that provides more specific information about individual services performed by healthcare professionals such as nurses or physicians who work within hospitals/clinics across America today! Below are the pathology codes that billing companies use: Field Code Range Anatomic Pathology 88000 – 88099 Hematology and Coagulation 85002 – 85999 Clinical Pathology Consultation 80500 – 80502 Surgical Pathology 88300 – 88399 Urinalysis 81000 – 81099 Molecular Pathology 81200 – 81479 Drug Testing 80100 – 80104 Chemistry 82000 – 84999 Cytopathology 88104 – 88199 Microbiology 87001 – 87999 Here are the top ICD-10 codes for pathology coding – - ICD-10-CM Code K29.50 – Medical ailments related to gastritis - ICD-10-CM Code K20.8 – Medical diagnosis of the allergic inflammatory condition in the esophagus - ICD-10-CM Code N20.1 – Code for kidney stones - ICD-10-CM Code C50.911 – Code that helps specify Breast cancer in women EMR System in Pathology Billing An EMR system is software that hospitals to manage patient records, including their medical history. Many doctors also use it to bill their patients, and it can be an essential tool for the medical billing industry. EMR is also known as Electronic Health Record (EHR) system.
88300	SURGICAL TISSUE, GROSS ONLY	HCPCS	It contains detailed descriptions of each procedure and any associated equipment costs and facility fees that may be involved with performing said procedure/treatment on a patient at an institution like yours! - HCPCS (Healthcare Common Procedure Coding System) – Another widely-used coding system that provides more specific information about individual services performed by healthcare professionals such as nurses or physicians who work within hospitals/clinics across America today! Below are the pathology codes that billing companies use: Field Code Range Anatomic Pathology 88000 – 88099 Hematology and Coagulation 85002 – 85999 Clinical Pathology Consultation 80500 – 80502 Surgical Pathology 88300 – 88399 Urinalysis 81000 – 81099 Molecular Pathology 81200 – 81479 Drug Testing 80100 – 80104 Chemistry 82000 – 84999 Cytopathology 88104 – 88199 Microbiology 87001 – 87999 Here are the top ICD-10 codes for pathology coding – - ICD-10-CM Code K29.50 – Medical ailments related to gastritis - ICD-10-CM Code K20.8 – Medical diagnosis of the allergic inflammatory condition in the esophagus - ICD-10-CM Code N20.1 – Code for kidney stones - ICD-10-CM Code C50.911 – Code that helps specify Breast cancer in women EMR System in Pathology Billing An EMR system is software that hospitals to manage patient records, including their medical history. Many doctors also use it to bill their patients, and it can be an essential tool for the medical billing industry. EMR is also known as Electronic Health Record (EHR) system.
82000	Assay of blood acetaldehyde	HCPCS	It contains detailed descriptions of each procedure and any associated equipment costs and facility fees that may be involved with performing said procedure/treatment on a patient at an institution like yours! - HCPCS (Healthcare Common Procedure Coding System) – Another widely-used coding system that provides more specific information about individual services performed by healthcare professionals such as nurses or physicians who work within hospitals/clinics across America today! Below are the pathology codes that billing companies use: Field Code Range Anatomic Pathology 88000 – 88099 Hematology and Coagulation 85002 – 85999 Clinical Pathology Consultation 80500 – 80502 Surgical Pathology 88300 – 88399 Urinalysis 81000 – 81099 Molecular Pathology 81200 – 81479 Drug Testing 80100 – 80104 Chemistry 82000 – 84999 Cytopathology 88104 – 88199 Microbiology 87001 – 87999 Here are the top ICD-10 codes for pathology coding – - ICD-10-CM Code K29.50 – Medical ailments related to gastritis - ICD-10-CM Code K20.8 – Medical diagnosis of the allergic inflammatory condition in the esophagus - ICD-10-CM Code N20.1 – Code for kidney stones - ICD-10-CM Code C50.911 – Code that helps specify Breast cancer in women EMR System in Pathology Billing An EMR system is software that hospitals to manage patient records, including their medical history. Many doctors also use it to bill their patients, and it can be an essential tool for the medical billing industry. EMR is also known as Electronic Health Record (EHR) system.
81099	URINE COLLECTION	HCPCS	It contains detailed descriptions of each procedure and any associated equipment costs and facility fees that may be involved with performing said procedure/treatment on a patient at an institution like yours! - HCPCS (Healthcare Common Procedure Coding System) – Another widely-used coding system that provides more specific information about individual services performed by healthcare professionals such as nurses or physicians who work within hospitals/clinics across America today! Below are the pathology codes that billing companies use: Field Code Range Anatomic Pathology 88000 – 88099 Hematology and Coagulation 85002 – 85999 Clinical Pathology Consultation 80500 – 80502 Surgical Pathology 88300 – 88399 Urinalysis 81000 – 81099 Molecular Pathology 81200 – 81479 Drug Testing 80100 – 80104 Chemistry 82000 – 84999 Cytopathology 88104 – 88199 Microbiology 87001 – 87999 Here are the top ICD-10 codes for pathology coding – - ICD-10-CM Code K29.50 – Medical ailments related to gastritis - ICD-10-CM Code K20.8 – Medical diagnosis of the allergic inflammatory condition in the esophagus - ICD-10-CM Code N20.1 – Code for kidney stones - ICD-10-CM Code C50.911 – Code that helps specify Breast cancer in women EMR System in Pathology Billing An EMR system is software that hospitals to manage patient records, including their medical history. Many doctors also use it to bill their patients, and it can be an essential tool for the medical billing industry. EMR is also known as Electronic Health Record (EHR) system.
88399	HC UNLISTED SURGICAL PATHOLOGY PROCEDURE	HCPCS	It contains detailed descriptions of each procedure and any associated equipment costs and facility fees that may be involved with performing said procedure/treatment on a patient at an institution like yours! - HCPCS (Healthcare Common Procedure Coding System) – Another widely-used coding system that provides more specific information about individual services performed by healthcare professionals such as nurses or physicians who work within hospitals/clinics across America today! Below are the pathology codes that billing companies use: Field Code Range Anatomic Pathology 88000 – 88099 Hematology and Coagulation 85002 – 85999 Clinical Pathology Consultation 80500 – 80502 Surgical Pathology 88300 – 88399 Urinalysis 81000 – 81099 Molecular Pathology 81200 – 81479 Drug Testing 80100 – 80104 Chemistry 82000 – 84999 Cytopathology 88104 – 88199 Microbiology 87001 – 87999 Here are the top ICD-10 codes for pathology coding – - ICD-10-CM Code K29.50 – Medical ailments related to gastritis - ICD-10-CM Code K20.8 – Medical diagnosis of the allergic inflammatory condition in the esophagus - ICD-10-CM Code N20.1 – Code for kidney stones - ICD-10-CM Code C50.911 – Code that helps specify Breast cancer in women EMR System in Pathology Billing An EMR system is software that hospitals to manage patient records, including their medical history. Many doctors also use it to bill their patients, and it can be an essential tool for the medical billing industry. EMR is also known as Electronic Health Record (EHR) system.
81000	HC URINALYSIS, BY DIP STICK OR TABLET REAGENT; NON-AUTOMATED, WI	HCPCS	It contains detailed descriptions of each procedure and any associated equipment costs and facility fees that may be involved with performing said procedure/treatment on a patient at an institution like yours! - HCPCS (Healthcare Common Procedure Coding System) – Another widely-used coding system that provides more specific information about individual services performed by healthcare professionals such as nurses or physicians who work within hospitals/clinics across America today! Below are the pathology codes that billing companies use: Field Code Range Anatomic Pathology 88000 – 88099 Hematology and Coagulation 85002 – 85999 Clinical Pathology Consultation 80500 – 80502 Surgical Pathology 88300 – 88399 Urinalysis 81000 – 81099 Molecular Pathology 81200 – 81479 Drug Testing 80100 – 80104 Chemistry 82000 – 84999 Cytopathology 88104 – 88199 Microbiology 87001 – 87999 Here are the top ICD-10 codes for pathology coding – - ICD-10-CM Code K29.50 – Medical ailments related to gastritis - ICD-10-CM Code K20.8 – Medical diagnosis of the allergic inflammatory condition in the esophagus - ICD-10-CM Code N20.1 – Code for kidney stones - ICD-10-CM Code C50.911 – Code that helps specify Breast cancer in women EMR System in Pathology Billing An EMR system is software that hospitals to manage patient records, including their medical history. Many doctors also use it to bill their patients, and it can be an essential tool for the medical billing industry. EMR is also known as Electronic Health Record (EHR) system.
88104	HC CYTOPATHOLOGY, FLUIDS, WASHINGS OR BRUSHINGS, EXCEPT CERVICAL	HCPCS	It contains detailed descriptions of each procedure and any associated equipment costs and facility fees that may be involved with performing said procedure/treatment on a patient at an institution like yours! - HCPCS (Healthcare Common Procedure Coding System) – Another widely-used coding system that provides more specific information about individual services performed by healthcare professionals such as nurses or physicians who work within hospitals/clinics across America today! Below are the pathology codes that billing companies use: Field Code Range Anatomic Pathology 88000 – 88099 Hematology and Coagulation 85002 – 85999 Clinical Pathology Consultation 80500 – 80502 Surgical Pathology 88300 – 88399 Urinalysis 81000 – 81099 Molecular Pathology 81200 – 81479 Drug Testing 80100 – 80104 Chemistry 82000 – 84999 Cytopathology 88104 – 88199 Microbiology 87001 – 87999 Here are the top ICD-10 codes for pathology coding – - ICD-10-CM Code K29.50 – Medical ailments related to gastritis - ICD-10-CM Code K20.8 – Medical diagnosis of the allergic inflammatory condition in the esophagus - ICD-10-CM Code N20.1 – Code for kidney stones - ICD-10-CM Code C50.911 – Code that helps specify Breast cancer in women EMR System in Pathology Billing An EMR system is software that hospitals to manage patient records, including their medical history. Many doctors also use it to bill their patients, and it can be an essential tool for the medical billing industry. EMR is also known as Electronic Health Record (EHR) system.
81479	UNLISTED MOLECULAR PATHOLOGY PROCEDURE	HCPCS	It contains detailed descriptions of each procedure and any associated equipment costs and facility fees that may be involved with performing said procedure/treatment on a patient at an institution like yours! - HCPCS (Healthcare Common Procedure Coding System) – Another widely-used coding system that provides more specific information about individual services performed by healthcare professionals such as nurses or physicians who work within hospitals/clinics across America today! Below are the pathology codes that billing companies use: Field Code Range Anatomic Pathology 88000 – 88099 Hematology and Coagulation 85002 – 85999 Clinical Pathology Consultation 80500 – 80502 Surgical Pathology 88300 – 88399 Urinalysis 81000 – 81099 Molecular Pathology 81200 – 81479 Drug Testing 80100 – 80104 Chemistry 82000 – 84999 Cytopathology 88104 – 88199 Microbiology 87001 – 87999 Here are the top ICD-10 codes for pathology coding – - ICD-10-CM Code K29.50 – Medical ailments related to gastritis - ICD-10-CM Code K20.8 – Medical diagnosis of the allergic inflammatory condition in the esophagus - ICD-10-CM Code N20.1 – Code for kidney stones - ICD-10-CM Code C50.911 – Code that helps specify Breast cancer in women EMR System in Pathology Billing An EMR system is software that hospitals to manage patient records, including their medical history. Many doctors also use it to bill their patients, and it can be an essential tool for the medical billing industry. EMR is also known as Electronic Health Record (EHR) system.
87001	Small animal inoculation	HCPCS	It contains detailed descriptions of each procedure and any associated equipment costs and facility fees that may be involved with performing said procedure/treatment on a patient at an institution like yours! - HCPCS (Healthcare Common Procedure Coding System) – Another widely-used coding system that provides more specific information about individual services performed by healthcare professionals such as nurses or physicians who work within hospitals/clinics across America today! Below are the pathology codes that billing companies use: Field Code Range Anatomic Pathology 88000 – 88099 Hematology and Coagulation 85002 – 85999 Clinical Pathology Consultation 80500 – 80502 Surgical Pathology 88300 – 88399 Urinalysis 81000 – 81099 Molecular Pathology 81200 – 81479 Drug Testing 80100 – 80104 Chemistry 82000 – 84999 Cytopathology 88104 – 88199 Microbiology 87001 – 87999 Here are the top ICD-10 codes for pathology coding – - ICD-10-CM Code K29.50 – Medical ailments related to gastritis - ICD-10-CM Code K20.8 – Medical diagnosis of the allergic inflammatory condition in the esophagus - ICD-10-CM Code N20.1 – Code for kidney stones - ICD-10-CM Code C50.911 – Code that helps specify Breast cancer in women EMR System in Pathology Billing An EMR system is software that hospitals to manage patient records, including their medical history. Many doctors also use it to bill their patients, and it can be an essential tool for the medical billing industry. EMR is also known as Electronic Health Record (EHR) system.
85002	HC BLEEDING TIME	HCPCS	It contains detailed descriptions of each procedure and any associated equipment costs and facility fees that may be involved with performing said procedure/treatment on a patient at an institution like yours! - HCPCS (Healthcare Common Procedure Coding System) – Another widely-used coding system that provides more specific information about individual services performed by healthcare professionals such as nurses or physicians who work within hospitals/clinics across America today! Below are the pathology codes that billing companies use: Field Code Range Anatomic Pathology 88000 – 88099 Hematology and Coagulation 85002 – 85999 Clinical Pathology Consultation 80500 – 80502 Surgical Pathology 88300 – 88399 Urinalysis 81000 – 81099 Molecular Pathology 81200 – 81479 Drug Testing 80100 – 80104 Chemistry 82000 – 84999 Cytopathology 88104 – 88199 Microbiology 87001 – 87999 Here are the top ICD-10 codes for pathology coding – - ICD-10-CM Code K29.50 – Medical ailments related to gastritis - ICD-10-CM Code K20.8 – Medical diagnosis of the allergic inflammatory condition in the esophagus - ICD-10-CM Code N20.1 – Code for kidney stones - ICD-10-CM Code C50.911 – Code that helps specify Breast cancer in women EMR System in Pathology Billing An EMR system is software that hospitals to manage patient records, including their medical history. Many doctors also use it to bill their patients, and it can be an essential tool for the medical billing industry. EMR is also known as Electronic Health Record (EHR) system.
88000	Autopsy (necropsy) gross	HCPCS	It contains detailed descriptions of each procedure and any associated equipment costs and facility fees that may be involved with performing said procedure/treatment on a patient at an institution like yours! - HCPCS (Healthcare Common Procedure Coding System) – Another widely-used coding system that provides more specific information about individual services performed by healthcare professionals such as nurses or physicians who work within hospitals/clinics across America today! Below are the pathology codes that billing companies use: Field Code Range Anatomic Pathology 88000 – 88099 Hematology and Coagulation 85002 – 85999 Clinical Pathology Consultation 80500 – 80502 Surgical Pathology 88300 – 88399 Urinalysis 81000 – 81099 Molecular Pathology 81200 – 81479 Drug Testing 80100 – 80104 Chemistry 82000 – 84999 Cytopathology 88104 – 88199 Microbiology 87001 – 87999 Here are the top ICD-10 codes for pathology coding – - ICD-10-CM Code K29.50 – Medical ailments related to gastritis - ICD-10-CM Code K20.8 – Medical diagnosis of the allergic inflammatory condition in the esophagus - ICD-10-CM Code N20.1 – Code for kidney stones - ICD-10-CM Code C50.911 – Code that helps specify Breast cancer in women EMR System in Pathology Billing An EMR system is software that hospitals to manage patient records, including their medical history. Many doctors also use it to bill their patients, and it can be an essential tool for the medical billing industry. EMR is also known as Electronic Health Record (EHR) system.
81200	HC UNIVERSAL CARRIER SCREEN	HCPCS	It contains detailed descriptions of each procedure and any associated equipment costs and facility fees that may be involved with performing said procedure/treatment on a patient at an institution like yours! - HCPCS (Healthcare Common Procedure Coding System) – Another widely-used coding system that provides more specific information about individual services performed by healthcare professionals such as nurses or physicians who work within hospitals/clinics across America today! Below are the pathology codes that billing companies use: Field Code Range Anatomic Pathology 88000 – 88099 Hematology and Coagulation 85002 – 85999 Clinical Pathology Consultation 80500 – 80502 Surgical Pathology 88300 – 88399 Urinalysis 81000 – 81099 Molecular Pathology 81200 – 81479 Drug Testing 80100 – 80104 Chemistry 82000 – 84999 Cytopathology 88104 – 88199 Microbiology 87001 – 87999 Here are the top ICD-10 codes for pathology coding – - ICD-10-CM Code K29.50 – Medical ailments related to gastritis - ICD-10-CM Code K20.8 – Medical diagnosis of the allergic inflammatory condition in the esophagus - ICD-10-CM Code N20.1 – Code for kidney stones - ICD-10-CM Code C50.911 – Code that helps specify Breast cancer in women EMR System in Pathology Billing An EMR system is software that hospitals to manage patient records, including their medical history. Many doctors also use it to bill their patients, and it can be an essential tool for the medical billing industry. EMR is also known as Electronic Health Record (EHR) system.
84999	UNLISTED CHEMISTRY PROCEDURE	HCPCS	It contains detailed descriptions of each procedure and any associated equipment costs and facility fees that may be involved with performing said procedure/treatment on a patient at an institution like yours! - HCPCS (Healthcare Common Procedure Coding System) – Another widely-used coding system that provides more specific information about individual services performed by healthcare professionals such as nurses or physicians who work within hospitals/clinics across America today! Below are the pathology codes that billing companies use: Field Code Range Anatomic Pathology 88000 – 88099 Hematology and Coagulation 85002 – 85999 Clinical Pathology Consultation 80500 – 80502 Surgical Pathology 88300 – 88399 Urinalysis 81000 – 81099 Molecular Pathology 81200 – 81479 Drug Testing 80100 – 80104 Chemistry 82000 – 84999 Cytopathology 88104 – 88199 Microbiology 87001 – 87999 Here are the top ICD-10 codes for pathology coding – - ICD-10-CM Code K29.50 – Medical ailments related to gastritis - ICD-10-CM Code K20.8 – Medical diagnosis of the allergic inflammatory condition in the esophagus - ICD-10-CM Code N20.1 – Code for kidney stones - ICD-10-CM Code C50.911 – Code that helps specify Breast cancer in women EMR System in Pathology Billing An EMR system is software that hospitals to manage patient records, including their medical history. Many doctors also use it to bill their patients, and it can be an essential tool for the medical billing industry. EMR is also known as Electronic Health Record (EHR) system.
80100	DRUG SCREEN QUALITATE/MULTI	HCPCS	It contains detailed descriptions of each procedure and any associated equipment costs and facility fees that may be involved with performing said procedure/treatment on a patient at an institution like yours! - HCPCS (Healthcare Common Procedure Coding System) – Another widely-used coding system that provides more specific information about individual services performed by healthcare professionals such as nurses or physicians who work within hospitals/clinics across America today! Below are the pathology codes that billing companies use: Field Code Range Anatomic Pathology 88000 – 88099 Hematology and Coagulation 85002 – 85999 Clinical Pathology Consultation 80500 – 80502 Surgical Pathology 88300 – 88399 Urinalysis 81000 – 81099 Molecular Pathology 81200 – 81479 Drug Testing 80100 – 80104 Chemistry 82000 – 84999 Cytopathology 88104 – 88199 Microbiology 87001 – 87999 Here are the top ICD-10 codes for pathology coding – - ICD-10-CM Code K29.50 – Medical ailments related to gastritis - ICD-10-CM Code K20.8 – Medical diagnosis of the allergic inflammatory condition in the esophagus - ICD-10-CM Code N20.1 – Code for kidney stones - ICD-10-CM Code C50.911 – Code that helps specify Breast cancer in women EMR System in Pathology Billing An EMR system is software that hospitals to manage patient records, including their medical history. Many doctors also use it to bill their patients, and it can be an essential tool for the medical billing industry. EMR is also known as Electronic Health Record (EHR) system.
88199	Unlisted cytopathology px	HCPCS	It contains detailed descriptions of each procedure and any associated equipment costs and facility fees that may be involved with performing said procedure/treatment on a patient at an institution like yours! - HCPCS (Healthcare Common Procedure Coding System) – Another widely-used coding system that provides more specific information about individual services performed by healthcare professionals such as nurses or physicians who work within hospitals/clinics across America today! Below are the pathology codes that billing companies use: Field Code Range Anatomic Pathology 88000 – 88099 Hematology and Coagulation 85002 – 85999 Clinical Pathology Consultation 80500 – 80502 Surgical Pathology 88300 – 88399 Urinalysis 81000 – 81099 Molecular Pathology 81200 – 81479 Drug Testing 80100 – 80104 Chemistry 82000 – 84999 Cytopathology 88104 – 88199 Microbiology 87001 – 87999 Here are the top ICD-10 codes for pathology coding – - ICD-10-CM Code K29.50 – Medical ailments related to gastritis - ICD-10-CM Code K20.8 – Medical diagnosis of the allergic inflammatory condition in the esophagus - ICD-10-CM Code N20.1 – Code for kidney stones - ICD-10-CM Code C50.911 – Code that helps specify Breast cancer in women EMR System in Pathology Billing An EMR system is software that hospitals to manage patient records, including their medical history. Many doctors also use it to bill their patients, and it can be an essential tool for the medical billing industry. EMR is also known as Electronic Health Record (EHR) system.
80502	Lab pathology consultation	HCPCS	It contains detailed descriptions of each procedure and any associated equipment costs and facility fees that may be involved with performing said procedure/treatment on a patient at an institution like yours! - HCPCS (Healthcare Common Procedure Coding System) – Another widely-used coding system that provides more specific information about individual services performed by healthcare professionals such as nurses or physicians who work within hospitals/clinics across America today! Below are the pathology codes that billing companies use: Field Code Range Anatomic Pathology 88000 – 88099 Hematology and Coagulation 85002 – 85999 Clinical Pathology Consultation 80500 – 80502 Surgical Pathology 88300 – 88399 Urinalysis 81000 – 81099 Molecular Pathology 81200 – 81479 Drug Testing 80100 – 80104 Chemistry 82000 – 84999 Cytopathology 88104 – 88199 Microbiology 87001 – 87999 Here are the top ICD-10 codes for pathology coding – - ICD-10-CM Code K29.50 – Medical ailments related to gastritis - ICD-10-CM Code K20.8 – Medical diagnosis of the allergic inflammatory condition in the esophagus - ICD-10-CM Code N20.1 – Code for kidney stones - ICD-10-CM Code C50.911 – Code that helps specify Breast cancer in women EMR System in Pathology Billing An EMR system is software that hospitals to manage patient records, including their medical history. Many doctors also use it to bill their patients, and it can be an essential tool for the medical billing industry. EMR is also known as Electronic Health Record (EHR) system.
87999	HC UNLISTED MICROBIOLOGY PROCEDURE	HCPCS	It contains detailed descriptions of each procedure and any associated equipment costs and facility fees that may be involved with performing said procedure/treatment on a patient at an institution like yours! - HCPCS (Healthcare Common Procedure Coding System) – Another widely-used coding system that provides more specific information about individual services performed by healthcare professionals such as nurses or physicians who work within hospitals/clinics across America today! Below are the pathology codes that billing companies use: Field Code Range Anatomic Pathology 88000 – 88099 Hematology and Coagulation 85002 – 85999 Clinical Pathology Consultation 80500 – 80502 Surgical Pathology 88300 – 88399 Urinalysis 81000 – 81099 Molecular Pathology 81200 – 81479 Drug Testing 80100 – 80104 Chemistry 82000 – 84999 Cytopathology 88104 – 88199 Microbiology 87001 – 87999 Here are the top ICD-10 codes for pathology coding – - ICD-10-CM Code K29.50 – Medical ailments related to gastritis - ICD-10-CM Code K20.8 – Medical diagnosis of the allergic inflammatory condition in the esophagus - ICD-10-CM Code N20.1 – Code for kidney stones - ICD-10-CM Code C50.911 – Code that helps specify Breast cancer in women EMR System in Pathology Billing An EMR system is software that hospitals to manage patient records, including their medical history. Many doctors also use it to bill their patients, and it can be an essential tool for the medical billing industry. EMR is also known as Electronic Health Record (EHR) system.
80104	Drug scrn 1+ class nonchromo	HCPCS	It contains detailed descriptions of each procedure and any associated equipment costs and facility fees that may be involved with performing said procedure/treatment on a patient at an institution like yours! - HCPCS (Healthcare Common Procedure Coding System) – Another widely-used coding system that provides more specific information about individual services performed by healthcare professionals such as nurses or physicians who work within hospitals/clinics across America today! Below are the pathology codes that billing companies use: Field Code Range Anatomic Pathology 88000 – 88099 Hematology and Coagulation 85002 – 85999 Clinical Pathology Consultation 80500 – 80502 Surgical Pathology 88300 – 88399 Urinalysis 81000 – 81099 Molecular Pathology 81200 – 81479 Drug Testing 80100 – 80104 Chemistry 82000 – 84999 Cytopathology 88104 – 88199 Microbiology 87001 – 87999 Here are the top ICD-10 codes for pathology coding – - ICD-10-CM Code K29.50 – Medical ailments related to gastritis - ICD-10-CM Code K20.8 – Medical diagnosis of the allergic inflammatory condition in the esophagus - ICD-10-CM Code N20.1 – Code for kidney stones - ICD-10-CM Code C50.911 – Code that helps specify Breast cancer in women EMR System in Pathology Billing An EMR system is software that hospitals to manage patient records, including their medical history. Many doctors also use it to bill their patients, and it can be an essential tool for the medical billing industry. EMR is also known as Electronic Health Record (EHR) system.
E2120	Pulse gen sys tx endolymp fl	HCPCS	Patients then place an ear-cuff in the external ear canal and treat themselves for 3 minutes, 3 times daily. Treatment is continued for as long as patients find themselves in a period of attacks of vertigo. In 1999, the Meniett® device (Medtronic, Minneapolis, MN) received clearance to market through a U.S. Food and Drug Administration (FDA) 510(k) process specifically as a symptomatic treatment of Meniere's disease. Transtympanic micropressure applications as a treatment of Meniere`s disease are considered investigational. HCPCS code E2120, pulse generator system for tympanic treatment of inner ear endolymphatic fluid, describes the Meniett device.
E2120	Pulse gen sys tx endolymp fl	HCPCS	In 1999, the Meniett® device (Medtronic, Minneapolis, MN) received clearance to market through a U.S. Food and Drug Administration (FDA) 510(k) process specifically as a symptomatic treatment of Meniere's disease. Transtympanic micropressure applications as a treatment of Meniere`s disease are considered investigational. HCPCS code E2120, pulse generator system for tympanic treatment of inner ear endolymphatic fluid, describes the Meniett device. Use of the Meniett device requires a prior tympanostomy procedure, a novel indication for this common procedure. Plans with specific medical necessity criteria for tympanostomy may thus be able to prospectively identify claims for the Meniett device.
A4638	Repl batt pulse gen sys	HCPCS	2012. Available online at: http://guidance.nice.org.uk/IPG426/Guidance/pdf/English. Last accessed July 2014. \|ICD-9 Diagnosis\|\|Investigational for all diagnoses\| \|386.00 – 386.04\|\|Meniere`s disease code range\| \|HCPCS\|\|A4638\|\|Replacement battery for patient-owned ear generator, each\| \|E2120\|\|Pulse generator system for tympanic treatment of inner ear endolymphatic fluid\| \|ICD-10-CM (effective 10/1/15)\|\|Investigational for all diagnoses\| \|H81.01-H81.09\|\|Meniere`s disease code range\| \|ICD-10-PCS (effective 10/1/15)\|\|ICD-10-PCS codes are only used for inpatient services. There is no specific ICD-10-PCS code for the initiation of this therapy.\| Meniere`s Disease, Meniett Device Meniett Device, Meniere`s Disease \|04/29/03\|\|Add policy to Durable Medical Equipment section\|\|New policy\| \|12/17/03\|\|Replace policy\|\|;">New HCPCS codes added only; no other review\| \|04/16/04\|\|Replace policy\|\|Policy updated with literature review; no new literature, no change in policy statement\| \|11/9/04\|\|Replace policy\|\|Policy updated with literature and review of randomized study.
E2120	Pulse gen sys tx endolymp fl	HCPCS	2012. Available online at: http://guidance.nice.org.uk/IPG426/Guidance/pdf/English. Last accessed July 2014. \|ICD-9 Diagnosis\|\|Investigational for all diagnoses\| \|386.00 – 386.04\|\|Meniere`s disease code range\| \|HCPCS\|\|A4638\|\|Replacement battery for patient-owned ear generator, each\| \|E2120\|\|Pulse generator system for tympanic treatment of inner ear endolymphatic fluid\| \|ICD-10-CM (effective 10/1/15)\|\|Investigational for all diagnoses\| \|H81.01-H81.09\|\|Meniere`s disease code range\| \|ICD-10-PCS (effective 10/1/15)\|\|ICD-10-PCS codes are only used for inpatient services. There is no specific ICD-10-PCS code for the initiation of this therapy.\| Meniere`s Disease, Meniett Device Meniett Device, Meniere`s Disease \|04/29/03\|\|Add policy to Durable Medical Equipment section\|\|New policy\| \|12/17/03\|\|Replace policy\|\|;">New HCPCS codes added only; no other review\| \|04/16/04\|\|Replace policy\|\|Policy updated with literature review; no new literature, no change in policy statement\| \|11/9/04\|\|Replace policy\|\|Policy updated with literature and review of randomized study.
A4638	Repl batt pulse gen sys	HCPCS	Available online at: http://guidance.nice.org.uk/IPG426/Guidance/pdf/English. Last accessed July 2014. \|ICD-9 Diagnosis\|\|Investigational for all diagnoses\| \|386.00 – 386.04\|\|Meniere`s disease code range\| \|HCPCS\|\|A4638\|\|Replacement battery for patient-owned ear generator, each\| \|E2120\|\|Pulse generator system for tympanic treatment of inner ear endolymphatic fluid\| \|ICD-10-CM (effective 10/1/15)\|\|Investigational for all diagnoses\| \|H81.01-H81.09\|\|Meniere`s disease code range\| \|ICD-10-PCS (effective 10/1/15)\|\|ICD-10-PCS codes are only used for inpatient services. There is no specific ICD-10-PCS code for the initiation of this therapy.\| Meniere`s Disease, Meniett Device Meniett Device, Meniere`s Disease \|04/29/03\|\|Add policy to Durable Medical Equipment section\|\|New policy\| \|12/17/03\|\|Replace policy\|\|;">New HCPCS codes added only; no other review\| \|04/16/04\|\|Replace policy\|\|Policy updated with literature review; no new literature, no change in policy statement\| \|11/9/04\|\|Replace policy\|\|Policy updated with literature and review of randomized study. Reference added; no change in policy statement\| \|08/17/05\|\|Replace policy\|\|Policy updated with literature search; no changes in policy statement\| \|04/17/07\|\|Replace policy\|\|Policy updated with literature search; reference numbers 6 and 7 added; no change in policy statement\| \|09/11/08\|\|Replace policy\|\|Policy updated with literature search; references 8-11 added; no change in policy statement\| \|10/06/09\|\|Replace policy\|\|Policy updated with literature search through July 2009; reference 11 added; policy statement unchanged\| \|10/08/10\|\|Replace policy\|\|Policy updated with literature search through July 2010; policy statement unchanged\| \|10/04/11\|\|Replace policy\|\|Policy updated with literature search through July 2011; policy statement unchanged\| \|10/11/12\|\|Replace policy\|\|Policy updated with literature search through August 2012; references 12 and 14 added; policy statement unchanged\| \|10/10/13\|\|Replace policy\|\|Policy updated with literature search through August 26, 2013; policy statement unchanged\| \|10/09/14\|\|Replace policy\|\|Policy updated with literature review through August 28, 2014; policy statement unchanged\|
E2120	Pulse gen sys tx endolymp fl	HCPCS	Available online at: http://guidance.nice.org.uk/IPG426/Guidance/pdf/English. Last accessed July 2014. \|ICD-9 Diagnosis\|\|Investigational for all diagnoses\| \|386.00 – 386.04\|\|Meniere`s disease code range\| \|HCPCS\|\|A4638\|\|Replacement battery for patient-owned ear generator, each\| \|E2120\|\|Pulse generator system for tympanic treatment of inner ear endolymphatic fluid\| \|ICD-10-CM (effective 10/1/15)\|\|Investigational for all diagnoses\| \|H81.01-H81.09\|\|Meniere`s disease code range\| \|ICD-10-PCS (effective 10/1/15)\|\|ICD-10-PCS codes are only used for inpatient services. There is no specific ICD-10-PCS code for the initiation of this therapy.\| Meniere`s Disease, Meniett Device Meniett Device, Meniere`s Disease \|04/29/03\|\|Add policy to Durable Medical Equipment section\|\|New policy\| \|12/17/03\|\|Replace policy\|\|;">New HCPCS codes added only; no other review\| \|04/16/04\|\|Replace policy\|\|Policy updated with literature review; no new literature, no change in policy statement\| \|11/9/04\|\|Replace policy\|\|Policy updated with literature and review of randomized study. Reference added; no change in policy statement\| \|08/17/05\|\|Replace policy\|\|Policy updated with literature search; no changes in policy statement\| \|04/17/07\|\|Replace policy\|\|Policy updated with literature search; reference numbers 6 and 7 added; no change in policy statement\| \|09/11/08\|\|Replace policy\|\|Policy updated with literature search; references 8-11 added; no change in policy statement\| \|10/06/09\|\|Replace policy\|\|Policy updated with literature search through July 2009; reference 11 added; policy statement unchanged\| \|10/08/10\|\|Replace policy\|\|Policy updated with literature search through July 2010; policy statement unchanged\| \|10/04/11\|\|Replace policy\|\|Policy updated with literature search through July 2011; policy statement unchanged\| \|10/11/12\|\|Replace policy\|\|Policy updated with literature search through August 2012; references 12 and 14 added; policy statement unchanged\| \|10/10/13\|\|Replace policy\|\|Policy updated with literature search through August 26, 2013; policy statement unchanged\| \|10/09/14\|\|Replace policy\|\|Policy updated with literature review through August 28, 2014; policy statement unchanged\|
A4638	Repl batt pulse gen sys	HCPCS	Last accessed July 2014. \|ICD-9 Diagnosis\|\|Investigational for all diagnoses\| \|386.00 – 386.04\|\|Meniere`s disease code range\| \|HCPCS\|\|A4638\|\|Replacement battery for patient-owned ear generator, each\| \|E2120\|\|Pulse generator system for tympanic treatment of inner ear endolymphatic fluid\| \|ICD-10-CM (effective 10/1/15)\|\|Investigational for all diagnoses\| \|H81.01-H81.09\|\|Meniere`s disease code range\| \|ICD-10-PCS (effective 10/1/15)\|\|ICD-10-PCS codes are only used for inpatient services. There is no specific ICD-10-PCS code for the initiation of this therapy.\| Meniere`s Disease, Meniett Device Meniett Device, Meniere`s Disease \|04/29/03\|\|Add policy to Durable Medical Equipment section\|\|New policy\| \|12/17/03\|\|Replace policy\|\|;">New HCPCS codes added only; no other review\| \|04/16/04\|\|Replace policy\|\|Policy updated with literature review; no new literature, no change in policy statement\| \|11/9/04\|\|Replace policy\|\|Policy updated with literature and review of randomized study. Reference added; no change in policy statement\| \|08/17/05\|\|Replace policy\|\|Policy updated with literature search; no changes in policy statement\| \|04/17/07\|\|Replace policy\|\|Policy updated with literature search; reference numbers 6 and 7 added; no change in policy statement\| \|09/11/08\|\|Replace policy\|\|Policy updated with literature search; references 8-11 added; no change in policy statement\| \|10/06/09\|\|Replace policy\|\|Policy updated with literature search through July 2009; reference 11 added; policy statement unchanged\| \|10/08/10\|\|Replace policy\|\|Policy updated with literature search through July 2010; policy statement unchanged\| \|10/04/11\|\|Replace policy\|\|Policy updated with literature search through July 2011; policy statement unchanged\| \|10/11/12\|\|Replace policy\|\|Policy updated with literature search through August 2012; references 12 and 14 added; policy statement unchanged\| \|10/10/13\|\|Replace policy\|\|Policy updated with literature search through August 26, 2013; policy statement unchanged\| \|10/09/14\|\|Replace policy\|\|Policy updated with literature review through August 28, 2014; policy statement unchanged\|
E2120	Pulse gen sys tx endolymp fl	HCPCS	Last accessed July 2014. \|ICD-9 Diagnosis\|\|Investigational for all diagnoses\| \|386.00 – 386.04\|\|Meniere`s disease code range\| \|HCPCS\|\|A4638\|\|Replacement battery for patient-owned ear generator, each\| \|E2120\|\|Pulse generator system for tympanic treatment of inner ear endolymphatic fluid\| \|ICD-10-CM (effective 10/1/15)\|\|Investigational for all diagnoses\| \|H81.01-H81.09\|\|Meniere`s disease code range\| \|ICD-10-PCS (effective 10/1/15)\|\|ICD-10-PCS codes are only used for inpatient services. There is no specific ICD-10-PCS code for the initiation of this therapy.\| Meniere`s Disease, Meniett Device Meniett Device, Meniere`s Disease \|04/29/03\|\|Add policy to Durable Medical Equipment section\|\|New policy\| \|12/17/03\|\|Replace policy\|\|;">New HCPCS codes added only; no other review\| \|04/16/04\|\|Replace policy\|\|Policy updated with literature review; no new literature, no change in policy statement\| \|11/9/04\|\|Replace policy\|\|Policy updated with literature and review of randomized study. Reference added; no change in policy statement\| \|08/17/05\|\|Replace policy\|\|Policy updated with literature search; no changes in policy statement\| \|04/17/07\|\|Replace policy\|\|Policy updated with literature search; reference numbers 6 and 7 added; no change in policy statement\| \|09/11/08\|\|Replace policy\|\|Policy updated with literature search; references 8-11 added; no change in policy statement\| \|10/06/09\|\|Replace policy\|\|Policy updated with literature search through July 2009; reference 11 added; policy statement unchanged\| \|10/08/10\|\|Replace policy\|\|Policy updated with literature search through July 2010; policy statement unchanged\| \|10/04/11\|\|Replace policy\|\|Policy updated with literature search through July 2011; policy statement unchanged\| \|10/11/12\|\|Replace policy\|\|Policy updated with literature search through August 2012; references 12 and 14 added; policy statement unchanged\| \|10/10/13\|\|Replace policy\|\|Policy updated with literature search through August 26, 2013; policy statement unchanged\| \|10/09/14\|\|Replace policy\|\|Policy updated with literature review through August 28, 2014; policy statement unchanged\|
A4638	Repl batt pulse gen sys	HCPCS	\|ICD-9 Diagnosis\|\|Investigational for all diagnoses\| \|386.00 – 386.04\|\|Meniere`s disease code range\| \|HCPCS\|\|A4638\|\|Replacement battery for patient-owned ear generator, each\| \|E2120\|\|Pulse generator system for tympanic treatment of inner ear endolymphatic fluid\| \|ICD-10-CM (effective 10/1/15)\|\|Investigational for all diagnoses\| \|H81.01-H81.09\|\|Meniere`s disease code range\| \|ICD-10-PCS (effective 10/1/15)\|\|ICD-10-PCS codes are only used for inpatient services. There is no specific ICD-10-PCS code for the initiation of this therapy.\| Meniere`s Disease, Meniett Device Meniett Device, Meniere`s Disease \|04/29/03\|\|Add policy to Durable Medical Equipment section\|\|New policy\| \|12/17/03\|\|Replace policy\|\|;">New HCPCS codes added only; no other review\| \|04/16/04\|\|Replace policy\|\|Policy updated with literature review; no new literature, no change in policy statement\| \|11/9/04\|\|Replace policy\|\|Policy updated with literature and review of randomized study. Reference added; no change in policy statement\| \|08/17/05\|\|Replace policy\|\|Policy updated with literature search; no changes in policy statement\| \|04/17/07\|\|Replace policy\|\|Policy updated with literature search; reference numbers 6 and 7 added; no change in policy statement\| \|09/11/08\|\|Replace policy\|\|Policy updated with literature search; references 8-11 added; no change in policy statement\| \|10/06/09\|\|Replace policy\|\|Policy updated with literature search through July 2009; reference 11 added; policy statement unchanged\| \|10/08/10\|\|Replace policy\|\|Policy updated with literature search through July 2010; policy statement unchanged\| \|10/04/11\|\|Replace policy\|\|Policy updated with literature search through July 2011; policy statement unchanged\| \|10/11/12\|\|Replace policy\|\|Policy updated with literature search through August 2012; references 12 and 14 added; policy statement unchanged\| \|10/10/13\|\|Replace policy\|\|Policy updated with literature search through August 26, 2013; policy statement unchanged\| \|10/09/14\|\|Replace policy\|\|Policy updated with literature review through August 28, 2014; policy statement unchanged\|
E2120	Pulse gen sys tx endolymp fl	HCPCS	\|ICD-9 Diagnosis\|\|Investigational for all diagnoses\| \|386.00 – 386.04\|\|Meniere`s disease code range\| \|HCPCS\|\|A4638\|\|Replacement battery for patient-owned ear generator, each\| \|E2120\|\|Pulse generator system for tympanic treatment of inner ear endolymphatic fluid\| \|ICD-10-CM (effective 10/1/15)\|\|Investigational for all diagnoses\| \|H81.01-H81.09\|\|Meniere`s disease code range\| \|ICD-10-PCS (effective 10/1/15)\|\|ICD-10-PCS codes are only used for inpatient services. There is no specific ICD-10-PCS code for the initiation of this therapy.\| Meniere`s Disease, Meniett Device Meniett Device, Meniere`s Disease \|04/29/03\|\|Add policy to Durable Medical Equipment section\|\|New policy\| \|12/17/03\|\|Replace policy\|\|;">New HCPCS codes added only; no other review\| \|04/16/04\|\|Replace policy\|\|Policy updated with literature review; no new literature, no change in policy statement\| \|11/9/04\|\|Replace policy\|\|Policy updated with literature and review of randomized study. Reference added; no change in policy statement\| \|08/17/05\|\|Replace policy\|\|Policy updated with literature search; no changes in policy statement\| \|04/17/07\|\|Replace policy\|\|Policy updated with literature search; reference numbers 6 and 7 added; no change in policy statement\| \|09/11/08\|\|Replace policy\|\|Policy updated with literature search; references 8-11 added; no change in policy statement\| \|10/06/09\|\|Replace policy\|\|Policy updated with literature search through July 2009; reference 11 added; policy statement unchanged\| \|10/08/10\|\|Replace policy\|\|Policy updated with literature search through July 2010; policy statement unchanged\| \|10/04/11\|\|Replace policy\|\|Policy updated with literature search through July 2011; policy statement unchanged\| \|10/11/12\|\|Replace policy\|\|Policy updated with literature search through August 2012; references 12 and 14 added; policy statement unchanged\| \|10/10/13\|\|Replace policy\|\|Policy updated with literature search through August 26, 2013; policy statement unchanged\| \|10/09/14\|\|Replace policy\|\|Policy updated with literature review through August 28, 2014; policy statement unchanged\|
J9000	INJECTION, DOXORUBICIN HYDROCHLORIDE, 10 MG	HCPCS	Investigative service is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized by certifying boards and/or approving or licensing agencies or published peer review criteria as standard, effective medical practice for the treatment of the condition being treated and as such therefore is not considered medically necessary. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy.
G0364	HC BONE MARROW ASPIRATE & BIOPSY	HCPCS	Investigative service is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized by certifying boards and/or approving or licensing agencies or published peer review criteria as standard, effective medical practice for the treatment of the condition being treated and as such therefore is not considered medically necessary. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy.
J9999	Not otherwise classified, antineoplastic drugs	HCPCS	Investigative service is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized by certifying boards and/or approving or licensing agencies or published peer review criteria as standard, effective medical practice for the treatment of the condition being treated and as such therefore is not considered medically necessary. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy.
38230	PR BONE MARROW HARVEST TRANSPLANTATION ALLOGENEIC	HCPCS	Investigative service is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized by certifying boards and/or approving or licensing agencies or published peer review criteria as standard, effective medical practice for the treatment of the condition being treated and as such therefore is not considered medically necessary. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy.
86812	Immunologic analysis for autoimmune disease, A, B, or C, single antigen	HCPCS	Investigative service is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized by certifying boards and/or approving or licensing agencies or published peer review criteria as standard, effective medical practice for the treatment of the condition being treated and as such therefore is not considered medically necessary. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy.
86822	Lymphocyte culture primed	HCPCS	Investigative service is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized by certifying boards and/or approving or licensing agencies or published peer review criteria as standard, effective medical practice for the treatment of the condition being treated and as such therefore is not considered medically necessary. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy.
38204	PR MGMT RCP HEMATOP PROGENITOR CELL DONOR &ACQUISJ	HCPCS	Investigative service is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized by certifying boards and/or approving or licensing agencies or published peer review criteria as standard, effective medical practice for the treatment of the condition being treated and as such therefore is not considered medically necessary. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy.
G0355	CHEMO ADMN SUBQ/IM NONHORMONAL ANTINEOPLASTIC	HCPCS	Investigative service is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized by certifying boards and/or approving or licensing agencies or published peer review criteria as standard, effective medical practice for the treatment of the condition being treated and as such therefore is not considered medically necessary. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy.
J9000	INJECTION, DOXORUBICIN HYDROCHLORIDE, 10 MG	HCPCS	The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy. Policy description updated.
G0364	HC BONE MARROW ASPIRATE & BIOPSY	HCPCS	The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy. Policy description updated.
J9999	Not otherwise classified, antineoplastic drugs	HCPCS	The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy. Policy description updated.
38230	PR BONE MARROW HARVEST TRANSPLANTATION ALLOGENEIC	HCPCS	The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy. Policy description updated.
86812	Immunologic analysis for autoimmune disease, A, B, or C, single antigen	HCPCS	The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy. Policy description updated.
86822	Lymphocyte culture primed	HCPCS	The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy. Policy description updated.
38204	PR MGMT RCP HEMATOP PROGENITOR CELL DONOR &ACQUISJ	HCPCS	The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy. Policy description updated.
G0355	CHEMO ADMN SUBQ/IM NONHORMONAL ANTINEOPLASTIC	HCPCS	The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy. Policy description updated.
J9000	INJECTION, DOXORUBICIN HYDROCHLORIDE, 10 MG	HCPCS	POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy. Policy description updated. Policy statement changed to state that autologous consolidation therapy in patients with previously untreated embryonal tumors showing complete or partial response to, or stable disease after, induction therapy is now considered medically necessary.
G0364	HC BONE MARROW ASPIRATE & BIOPSY	HCPCS	POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy. Policy description updated. Policy statement changed to state that autologous consolidation therapy in patients with previously untreated embryonal tumors showing complete or partial response to, or stable disease after, induction therapy is now considered medically necessary.
J9999	Not otherwise classified, antineoplastic drugs	HCPCS	POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy. Policy description updated. Policy statement changed to state that autologous consolidation therapy in patients with previously untreated embryonal tumors showing complete or partial response to, or stable disease after, induction therapy is now considered medically necessary.
38230	PR BONE MARROW HARVEST TRANSPLANTATION ALLOGENEIC	HCPCS	POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy. Policy description updated. Policy statement changed to state that autologous consolidation therapy in patients with previously untreated embryonal tumors showing complete or partial response to, or stable disease after, induction therapy is now considered medically necessary.
86812	Immunologic analysis for autoimmune disease, A, B, or C, single antigen	HCPCS	POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy. Policy description updated. Policy statement changed to state that autologous consolidation therapy in patients with previously untreated embryonal tumors showing complete or partial response to, or stable disease after, induction therapy is now considered medically necessary.
86822	Lymphocyte culture primed	HCPCS	POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy. Policy description updated. Policy statement changed to state that autologous consolidation therapy in patients with previously untreated embryonal tumors showing complete or partial response to, or stable disease after, induction therapy is now considered medically necessary.
38204	PR MGMT RCP HEMATOP PROGENITOR CELL DONOR &ACQUISJ	HCPCS	POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy. Policy description updated. Policy statement changed to state that autologous consolidation therapy in patients with previously untreated embryonal tumors showing complete or partial response to, or stable disease after, induction therapy is now considered medically necessary.
G0355	CHEMO ADMN SUBQ/IM NONHORMONAL ANTINEOPLASTIC	HCPCS	POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.28 per approval by Medical Policy Advisory Committee (MPAC) 6/25/2004: Code Reference section completed 11/18/2004: Review by MPAC, no changes 10/26/2005: Code Reference section updated, CPT codes 38230, G0355 - G0364 added to the covered table, 38204, 86812 - 86822 added to the non-covered table, J9000 - J9999 deleted, ICD9 procedure codes 41.01, 41.09 added to the covered table, 41.02, 41.03 added to the non-covered table 3/21/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/21/2007: Policy reviewed, description of syngeneic and allogeneic donor types added. No change to policy statements 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 5/21/2008: Policy reviewed, no changes 04/26/2010: Title changed from “High-Dose Chemotherapy with Autologous Stem-Cell Support for Primitive Neuroectodermal Tumors (PNET) of the CNS and Ependymoma” to “Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma.” The term “PNET” was changed to “embryonal tumors” throughout the policy. Policy description updated. Policy statement changed to state that autologous consolidation therapy in patients with previously untreated embryonal tumors showing complete or partial response to, or stable disease after, induction therapy is now considered medically necessary.
86816	HC HLA TYPING DR/DQ SINGLE AG	HCPCS	Policy statement reworded and ependymoma and embryonal CNS tumors are addressed separately. FEP and State and School Employee verbiage added to the Policy Exceptions section. Added new CPT codes 86825 and 86826. Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table.
86826	Hla x-match noncytotoxc addl	HCPCS	Policy statement reworded and ependymoma and embryonal CNS tumors are addressed separately. FEP and State and School Employee verbiage added to the Policy Exceptions section. Added new CPT codes 86825 and 86826. Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table.
S2140	Cord blood harvesting for transplantation, allogeneic	HCPCS	Policy statement reworded and ependymoma and embryonal CNS tumors are addressed separately. FEP and State and School Employee verbiage added to the Policy Exceptions section. Added new CPT codes 86825 and 86826. Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table.
86821	Lymphocyte culture mixed	HCPCS	Policy statement reworded and ependymoma and embryonal CNS tumors are addressed separately. FEP and State and School Employee verbiage added to the Policy Exceptions section. Added new CPT codes 86825 and 86826. Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table.
86813	HC HLA TYPING; A, B, OR C, MULTIPLE ANTIGENS	HCPCS	Policy statement reworded and ependymoma and embryonal CNS tumors are addressed separately. FEP and State and School Employee verbiage added to the Policy Exceptions section. Added new CPT codes 86825 and 86826. Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table.
86822	Lymphocyte culture primed	HCPCS	Policy statement reworded and ependymoma and embryonal CNS tumors are addressed separately. FEP and State and School Employee verbiage added to the Policy Exceptions section. Added new CPT codes 86825 and 86826. Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table.
86812	Immunologic analysis for autoimmune disease, A, B, or C, single antigen	HCPCS	Policy statement reworded and ependymoma and embryonal CNS tumors are addressed separately. FEP and State and School Employee verbiage added to the Policy Exceptions section. Added new CPT codes 86825 and 86826. Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table.
86825	X-MATCHAHG	HCPCS	Policy statement reworded and ependymoma and embryonal CNS tumors are addressed separately. FEP and State and School Employee verbiage added to the Policy Exceptions section. Added new CPT codes 86825 and 86826. Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table.
86817	HC HLA TYPING; DR/DQ, MULTIPLE ANTIGENS	HCPCS	Policy statement reworded and ependymoma and embryonal CNS tumors are addressed separately. FEP and State and School Employee verbiage added to the Policy Exceptions section. Added new CPT codes 86825 and 86826. Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table.
S2142	Cord blood-derived stem-cell transplantation, allogeneic	HCPCS	Policy statement reworded and ependymoma and embryonal CNS tumors are addressed separately. FEP and State and School Employee verbiage added to the Policy Exceptions section. Added new CPT codes 86825 and 86826. Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table.
86816	HC HLA TYPING DR/DQ SINGLE AG	HCPCS	Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no changes.
G0267	Bone marrow or psc harvest	CPT	Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no changes.
S2140	Cord blood harvesting for transplantation, allogeneic	HCPCS	Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no changes.
G0265	Cryopresevation Freeze+stora	CPT	Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no changes.
86813	HC HLA TYPING; A, B, OR C, MULTIPLE ANTIGENS	HCPCS	Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no changes.
86822	Lymphocyte culture primed	HCPCS	Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no changes.
86812	Immunologic analysis for autoimmune disease, A, B, or C, single antigen	HCPCS	Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no changes.
G0266	Thawing + expansion froz cel	CPT	Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no changes.
86821	Lymphocyte culture mixed	HCPCS	Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no changes.
86817	HC HLA TYPING; DR/DQ, MULTIPLE ANTIGENS	HCPCS	Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no changes.
S2142	Cord blood-derived stem-cell transplantation, allogeneic	HCPCS	Removed CPT codes 86812, 86813, 86816, 86817, 86821, and 86822 from the non-covered table. Added HCPCS S2140 and S2142 to the non-covered table. Deleted HCPCS G0265, G0266, and G0267 from the code section as these codes were deleted on 12/31/2007. 12/28/2010: Policy reviewed; no changes. 01/17/2012: Policy reviewed; no changes.
15001	Wound prep, addl 100 sq cm	HCPCS	For additional information on the MS-DRG system, including yearly reviews and changes to the Madras, please view prior Inpatient Prospective Payment System (IPS) proposed and final rules located in the left navigational area of this page. CMS is hosting a listening session that will describe the Medicare-Severity Diagnosis-Related Group (MDR) Complication and Comorbidity (CC)/Major Complication and Comorbidity (MCC) Comprehensive Analysis discussed in the FY 2020 Inpatient Prospective Payment System (IPS) proposed and final rules. This listening session will include review of the methodology to measure the impact on resource use and will provide an opportunity for CMS to receive public input on this analysis and to address any clarifying questions in order to assist the public in formulating written comments on the current severity level designations for consideration for FY 2021 rule making. Under the Hopes version of the Madras developed for this requirement, to the extent feasible, the MS-DRG assignment for a given service furnished to an outpatient (billed using a Hopes code) is as similar as possible to the MS-DRG assignment for that service if furnished to an inpatient (billed using an ICD-10-PCS code). The HCPCS-MS-DRG definitions manual and software developed under the requirements of section 15001 of the 21st Century Cures Act (Public Law 114–255).
15001	Wound prep, addl 100 sq cm	HCPCS	CMS is hosting a listening session that will describe the Medicare-Severity Diagnosis-Related Group (MDR) Complication and Comorbidity (CC)/Major Complication and Comorbidity (MCC) Comprehensive Analysis discussed in the FY 2020 Inpatient Prospective Payment System (IPS) proposed and final rules. This listening session will include review of the methodology to measure the impact on resource use and will provide an opportunity for CMS to receive public input on this analysis and to address any clarifying questions in order to assist the public in formulating written comments on the current severity level designations for consideration for FY 2021 rule making. Under the Hopes version of the Madras developed for this requirement, to the extent feasible, the MS-DRG assignment for a given service furnished to an outpatient (billed using a Hopes code) is as similar as possible to the MS-DRG assignment for that service if furnished to an inpatient (billed using an ICD-10-PCS code). The HCPCS-MS-DRG definitions manual and software developed under the requirements of section 15001 of the 21st Century Cures Act (Public Law 114–255).
15001	Wound prep, addl 100 sq cm	HCPCS	This listening session will include review of the methodology to measure the impact on resource use and will provide an opportunity for CMS to receive public input on this analysis and to address any clarifying questions in order to assist the public in formulating written comments on the current severity level designations for consideration for FY 2021 rule making. Under the Hopes version of the Madras developed for this requirement, to the extent feasible, the MS-DRG assignment for a given service furnished to an outpatient (billed using a Hopes code) is as similar as possible to the MS-DRG assignment for that service if furnished to an inpatient (billed using an ICD-10-PCS code). The HCPCS-MS-DRG definitions manual and software developed under the requirements of section 15001 of the 21st Century Cures Act (Public Law 114–255).
1744	Endoscopic robotic assisted procedure	ICD	2009, 30 (6): 1297-1305. 10.1016/j.ridd.2009.05.006.PubMedView ArticleGoogle Scholar - World Health Organization (WHO): International Classification of Diseases; tenth Edition (ICD-10) Diagnostic Criteria for Research. 1993, WHO GenevaGoogle Scholar - Bakare MO, Ubochi VN, Okoroikpa IN, Aguocha CM, Ebigbo PO: Agreement between clinicians' and care givers' assessment of intelligence in Nigerian children with intellectual disability: 'ratio I.Q' as a viable option in the absence of standardized 'deviance IQ'tests in sub-Saharan Africa. Behav and Brain Funct. 2009, 5: 39-10.1186/1744-9081-5-39.View ArticleGoogle Scholar - Goodman R: The Strengths and Difficulties Questionnaire: a research note.
1500	New Technology - Level 1	APC	Complete list of Medical Abbreviations by. Acronym Finder, All Rights Reserved. PSP, HIPAA CPT is defined as Common Procedural Terminology (medical) very frequently. © 1988-2021, This book is an invaluable tool for everyone involved in learning, reading, writing or interpreting medical terminology. ChiroCode.com for Chiropractors CMS 1500 Claim Form Code-A-Note - Computer Assisted Coding Codapedia.com - Coding Forum Q&A CPT Codes DRGs & APCs DRG Grouper E/M Guidelines HCPCS Codes HCC Coding, Risk Adjustment ICD-10-CM Diagnosis Codes ICD-10-PCS Procedure Codes Medicare Guidelines NCCI Edits Validator NDC National Drug Codes NPI Look-Up Tool (National Provider … List page number 4 You can search by a CPT code or use a keyword to see what the associated CPT code for a service might be.
1500	New Technology - Level 1	APC	PSP, HIPAA CPT is defined as Common Procedural Terminology (medical) very frequently. © 1988-2021, This book is an invaluable tool for everyone involved in learning, reading, writing or interpreting medical terminology. ChiroCode.com for Chiropractors CMS 1500 Claim Form Code-A-Note - Computer Assisted Coding Codapedia.com - Coding Forum Q&A CPT Codes DRGs & APCs DRG Grouper E/M Guidelines HCPCS Codes HCC Coding, Risk Adjustment ICD-10-CM Diagnosis Codes ICD-10-PCS Procedure Codes Medicare Guidelines NCCI Edits Validator NDC National Drug Codes NPI Look-Up Tool (National Provider … List page number 4 You can search by a CPT code or use a keyword to see what the associated CPT code for a service might be. Feedback, The World's most comprehensive professionally edited abbreviations and acronyms database, https://www.acronymfinder.com/Science-and-Medicine/CPT.html, Cumulative Prospect Theory (risk decision), Central Place Theory (coined by Walter Christaller), Carnitine Palmityl Transferase Deficiency, Centre de Physique Théorique (French: Center for Theoretical Physics; University of Provence; France), Coherent Population Trapping (quantum optical physics), Centre de Production Thermique (French: Thermal Production Center), Capacité Pulmonaire Totale (French: Total Lung Capacity), Charge Parity Time (particle and nuclear physics), Compliant-Piled Tower (bottom-founded, free-standing offshore platform structure), Climate Predictability Tool (climate prediction software), Classical Plate Theory (continuum mechanics), Collarless Polished Tapered (type of hip replacement), Child-Pugh-Turcotte Score (liver disease assessment), Compound Pharmaceutical Technologies (Daphne, AL). Many of these abbreviations are well-known and in use outside medical settings, but different institutions can develop internal abbreviations that aren't generally recognized.
1500	New Technology - Level 1	APC	© 1988-2021, This book is an invaluable tool for everyone involved in learning, reading, writing or interpreting medical terminology. ChiroCode.com for Chiropractors CMS 1500 Claim Form Code-A-Note - Computer Assisted Coding Codapedia.com - Coding Forum Q&A CPT Codes DRGs & APCs DRG Grouper E/M Guidelines HCPCS Codes HCC Coding, Risk Adjustment ICD-10-CM Diagnosis Codes ICD-10-PCS Procedure Codes Medicare Guidelines NCCI Edits Validator NDC National Drug Codes NPI Look-Up Tool (National Provider … List page number 4 You can search by a CPT code or use a keyword to see what the associated CPT code for a service might be. Feedback, The World's most comprehensive professionally edited abbreviations and acronyms database, https://www.acronymfinder.com/Science-and-Medicine/CPT.html, Cumulative Prospect Theory (risk decision), Central Place Theory (coined by Walter Christaller), Carnitine Palmityl Transferase Deficiency, Centre de Physique Théorique (French: Center for Theoretical Physics; University of Provence; France), Coherent Population Trapping (quantum optical physics), Centre de Production Thermique (French: Thermal Production Center), Capacité Pulmonaire Totale (French: Total Lung Capacity), Charge Parity Time (particle and nuclear physics), Compliant-Piled Tower (bottom-founded, free-standing offshore platform structure), Climate Predictability Tool (climate prediction software), Classical Plate Theory (continuum mechanics), Collarless Polished Tapered (type of hip replacement), Child-Pugh-Turcotte Score (liver disease assessment), Compound Pharmaceutical Technologies (Daphne, AL). Many of these abbreviations are well-known and in use outside medical settings, but different institutions can develop internal abbreviations that aren't generally recognized. Medical terminology abbreviations list Here is the big list of Medical terminology abbreviation @—at A & P—anatomy and physiology ab—abortion abd—abdominal ... CPT—chest physical therapy CS—central supply CSF—cerebrospinal fluid CT—computer tomography CVA—cerebrovascular accident (stroke) Medical Billing and Coding Abbreviations Lists Expansions; ABN: Advance Beneficiary Notice: ACA: Affordable Care Act: AMA: American Medical Association: AOB: Assignment of Benefits: BIL: Bodily Injury Liability: CDM: Charges Description Master: CF: Conversion Factor: CHAMPUS: Civilian Health and Medical Program of the Uniformed Services: CHAMPVA Enter your term in the search box of the website or check out 50+ related full forms … Printer friendly.
G0358	IV PUSH TECHNIQUE EACH ADD SUBSTANCE/DRUG	HCPCS	In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.26 per approval by Medical Policy Advisory Committee (MPAC) 7/13/2004: Code Reference section completed 7/1/2004: Reviewed by MPAC; The following changed from investigational to medically necessary: "High-dose chemotherapy with allogeneic stem cell support is may be medically necessary to treat AML relapsing after prior therapy with high-dose chemotherapy and autologous stem cell support." 10/27/2005: Code Reference section updated; CPT-4 code 38230 added; ICD-9 Procedure 41.01, 41.02, 41.03, 41.09 added; HCPCS G0355, G0356, G0357, G0358, G0359, G0360, G0361, G0362, G0363, G0364 added, J9000-J9999 deleted 3/22/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/18/2007: Policy reviewed, no changes 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 7/14/2008: Policy updated; terminology modified but materially unchanged.
G0360	Each additional hr 1-8 hrs	HCPCS	In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.26 per approval by Medical Policy Advisory Committee (MPAC) 7/13/2004: Code Reference section completed 7/1/2004: Reviewed by MPAC; The following changed from investigational to medically necessary: "High-dose chemotherapy with allogeneic stem cell support is may be medically necessary to treat AML relapsing after prior therapy with high-dose chemotherapy and autologous stem cell support." 10/27/2005: Code Reference section updated; CPT-4 code 38230 added; ICD-9 Procedure 41.01, 41.02, 41.03, 41.09 added; HCPCS G0355, G0356, G0357, G0358, G0359, G0360, G0361, G0362, G0363, G0364 added, J9000-J9999 deleted 3/22/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/18/2007: Policy reviewed, no changes 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 7/14/2008: Policy updated; terminology modified but materially unchanged.
G0363	IRRIG IMPLANTED VENOUS ACESS DEVICE DRUG DEL SYS	HCPCS	In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.26 per approval by Medical Policy Advisory Committee (MPAC) 7/13/2004: Code Reference section completed 7/1/2004: Reviewed by MPAC; The following changed from investigational to medically necessary: "High-dose chemotherapy with allogeneic stem cell support is may be medically necessary to treat AML relapsing after prior therapy with high-dose chemotherapy and autologous stem cell support." 10/27/2005: Code Reference section updated; CPT-4 code 38230 added; ICD-9 Procedure 41.01, 41.02, 41.03, 41.09 added; HCPCS G0355, G0356, G0357, G0358, G0359, G0360, G0361, G0362, G0363, G0364 added, J9000-J9999 deleted 3/22/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/18/2007: Policy reviewed, no changes 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 7/14/2008: Policy updated; terminology modified but materially unchanged.
J9000	INJECTION, DOXORUBICIN HYDROCHLORIDE, 10 MG	HCPCS	In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.26 per approval by Medical Policy Advisory Committee (MPAC) 7/13/2004: Code Reference section completed 7/1/2004: Reviewed by MPAC; The following changed from investigational to medically necessary: "High-dose chemotherapy with allogeneic stem cell support is may be medically necessary to treat AML relapsing after prior therapy with high-dose chemotherapy and autologous stem cell support." 10/27/2005: Code Reference section updated; CPT-4 code 38230 added; ICD-9 Procedure 41.01, 41.02, 41.03, 41.09 added; HCPCS G0355, G0356, G0357, G0358, G0359, G0360, G0361, G0362, G0363, G0364 added, J9000-J9999 deleted 3/22/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/18/2007: Policy reviewed, no changes 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 7/14/2008: Policy updated; terminology modified but materially unchanged.
G0364	HC BONE MARROW ASPIRATE & BIOPSY	HCPCS	In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.26 per approval by Medical Policy Advisory Committee (MPAC) 7/13/2004: Code Reference section completed 7/1/2004: Reviewed by MPAC; The following changed from investigational to medically necessary: "High-dose chemotherapy with allogeneic stem cell support is may be medically necessary to treat AML relapsing after prior therapy with high-dose chemotherapy and autologous stem cell support." 10/27/2005: Code Reference section updated; CPT-4 code 38230 added; ICD-9 Procedure 41.01, 41.02, 41.03, 41.09 added; HCPCS G0355, G0356, G0357, G0358, G0359, G0360, G0361, G0362, G0363, G0364 added, J9000-J9999 deleted 3/22/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/18/2007: Policy reviewed, no changes 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 7/14/2008: Policy updated; terminology modified but materially unchanged.
G0362	Each add sequential infusion	HCPCS	In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.26 per approval by Medical Policy Advisory Committee (MPAC) 7/13/2004: Code Reference section completed 7/1/2004: Reviewed by MPAC; The following changed from investigational to medically necessary: "High-dose chemotherapy with allogeneic stem cell support is may be medically necessary to treat AML relapsing after prior therapy with high-dose chemotherapy and autologous stem cell support." 10/27/2005: Code Reference section updated; CPT-4 code 38230 added; ICD-9 Procedure 41.01, 41.02, 41.03, 41.09 added; HCPCS G0355, G0356, G0357, G0358, G0359, G0360, G0361, G0362, G0363, G0364 added, J9000-J9999 deleted 3/22/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/18/2007: Policy reviewed, no changes 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 7/14/2008: Policy updated; terminology modified but materially unchanged.
J9999	Not otherwise classified, antineoplastic drugs	HCPCS	In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.26 per approval by Medical Policy Advisory Committee (MPAC) 7/13/2004: Code Reference section completed 7/1/2004: Reviewed by MPAC; The following changed from investigational to medically necessary: "High-dose chemotherapy with allogeneic stem cell support is may be medically necessary to treat AML relapsing after prior therapy with high-dose chemotherapy and autologous stem cell support." 10/27/2005: Code Reference section updated; CPT-4 code 38230 added; ICD-9 Procedure 41.01, 41.02, 41.03, 41.09 added; HCPCS G0355, G0356, G0357, G0358, G0359, G0360, G0361, G0362, G0363, G0364 added, J9000-J9999 deleted 3/22/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/18/2007: Policy reviewed, no changes 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 7/14/2008: Policy updated; terminology modified but materially unchanged.
G0359	Chemotherapy IV one hr initi	HCPCS	In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.26 per approval by Medical Policy Advisory Committee (MPAC) 7/13/2004: Code Reference section completed 7/1/2004: Reviewed by MPAC; The following changed from investigational to medically necessary: "High-dose chemotherapy with allogeneic stem cell support is may be medically necessary to treat AML relapsing after prior therapy with high-dose chemotherapy and autologous stem cell support." 10/27/2005: Code Reference section updated; CPT-4 code 38230 added; ICD-9 Procedure 41.01, 41.02, 41.03, 41.09 added; HCPCS G0355, G0356, G0357, G0358, G0359, G0360, G0361, G0362, G0363, G0364 added, J9000-J9999 deleted 3/22/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/18/2007: Policy reviewed, no changes 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 7/14/2008: Policy updated; terminology modified but materially unchanged.
38230	PR BONE MARROW HARVEST TRANSPLANTATION ALLOGENEIC	HCPCS	In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.26 per approval by Medical Policy Advisory Committee (MPAC) 7/13/2004: Code Reference section completed 7/1/2004: Reviewed by MPAC; The following changed from investigational to medically necessary: "High-dose chemotherapy with allogeneic stem cell support is may be medically necessary to treat AML relapsing after prior therapy with high-dose chemotherapy and autologous stem cell support." 10/27/2005: Code Reference section updated; CPT-4 code 38230 added; ICD-9 Procedure 41.01, 41.02, 41.03, 41.09 added; HCPCS G0355, G0356, G0357, G0358, G0359, G0360, G0361, G0362, G0363, G0364 added, J9000-J9999 deleted 3/22/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/18/2007: Policy reviewed, no changes 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 7/14/2008: Policy updated; terminology modified but materially unchanged.
G0361	Prolong chemo infuse>8hrs pu	HCPCS	In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.26 per approval by Medical Policy Advisory Committee (MPAC) 7/13/2004: Code Reference section completed 7/1/2004: Reviewed by MPAC; The following changed from investigational to medically necessary: "High-dose chemotherapy with allogeneic stem cell support is may be medically necessary to treat AML relapsing after prior therapy with high-dose chemotherapy and autologous stem cell support." 10/27/2005: Code Reference section updated; CPT-4 code 38230 added; ICD-9 Procedure 41.01, 41.02, 41.03, 41.09 added; HCPCS G0355, G0356, G0357, G0358, G0359, G0360, G0361, G0362, G0363, G0364 added, J9000-J9999 deleted 3/22/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/18/2007: Policy reviewed, no changes 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 7/14/2008: Policy updated; terminology modified but materially unchanged.
G0357	IV PUSH TECHNIQUE SINGLE/INIT SUBSTANCE/DRUG	HCPCS	In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.26 per approval by Medical Policy Advisory Committee (MPAC) 7/13/2004: Code Reference section completed 7/1/2004: Reviewed by MPAC; The following changed from investigational to medically necessary: "High-dose chemotherapy with allogeneic stem cell support is may be medically necessary to treat AML relapsing after prior therapy with high-dose chemotherapy and autologous stem cell support." 10/27/2005: Code Reference section updated; CPT-4 code 38230 added; ICD-9 Procedure 41.01, 41.02, 41.03, 41.09 added; HCPCS G0355, G0356, G0357, G0358, G0359, G0360, G0361, G0362, G0363, G0364 added, J9000-J9999 deleted 3/22/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/18/2007: Policy reviewed, no changes 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 7/14/2008: Policy updated; terminology modified but materially unchanged.
G0356	HORMONAL ANTINEOPLASTIC	HCPCS	In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.26 per approval by Medical Policy Advisory Committee (MPAC) 7/13/2004: Code Reference section completed 7/1/2004: Reviewed by MPAC; The following changed from investigational to medically necessary: "High-dose chemotherapy with allogeneic stem cell support is may be medically necessary to treat AML relapsing after prior therapy with high-dose chemotherapy and autologous stem cell support." 10/27/2005: Code Reference section updated; CPT-4 code 38230 added; ICD-9 Procedure 41.01, 41.02, 41.03, 41.09 added; HCPCS G0355, G0356, G0357, G0358, G0359, G0360, G0361, G0362, G0363, G0364 added, J9000-J9999 deleted 3/22/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/18/2007: Policy reviewed, no changes 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 7/14/2008: Policy updated; terminology modified but materially unchanged.
G0355	CHEMO ADMN SUBQ/IM NONHORMONAL ANTINEOPLASTIC	HCPCS	In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting. The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.26 per approval by Medical Policy Advisory Committee (MPAC) 7/13/2004: Code Reference section completed 7/1/2004: Reviewed by MPAC; The following changed from investigational to medically necessary: "High-dose chemotherapy with allogeneic stem cell support is may be medically necessary to treat AML relapsing after prior therapy with high-dose chemotherapy and autologous stem cell support." 10/27/2005: Code Reference section updated; CPT-4 code 38230 added; ICD-9 Procedure 41.01, 41.02, 41.03, 41.09 added; HCPCS G0355, G0356, G0357, G0358, G0359, G0360, G0361, G0362, G0363, G0364 added, J9000-J9999 deleted 3/22/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/18/2007: Policy reviewed, no changes 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 7/14/2008: Policy updated; terminology modified but materially unchanged.
G0358	IV PUSH TECHNIQUE EACH ADD SUBSTANCE/DRUG	HCPCS	The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.26 per approval by Medical Policy Advisory Committee (MPAC) 7/13/2004: Code Reference section completed 7/1/2004: Reviewed by MPAC; The following changed from investigational to medically necessary: "High-dose chemotherapy with allogeneic stem cell support is may be medically necessary to treat AML relapsing after prior therapy with high-dose chemotherapy and autologous stem cell support." 10/27/2005: Code Reference section updated; CPT-4 code 38230 added; ICD-9 Procedure 41.01, 41.02, 41.03, 41.09 added; HCPCS G0355, G0356, G0357, G0358, G0359, G0360, G0361, G0362, G0363, G0364 added, J9000-J9999 deleted 3/22/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/18/2007: Policy reviewed, no changes 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 7/14/2008: Policy updated; terminology modified but materially unchanged. High dose chemotherapy terminology removed from title and policy statement and replaced with stem cell transplantation (SCT).
G0360	Each additional hr 1-8 hrs	HCPCS	The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.26 per approval by Medical Policy Advisory Committee (MPAC) 7/13/2004: Code Reference section completed 7/1/2004: Reviewed by MPAC; The following changed from investigational to medically necessary: "High-dose chemotherapy with allogeneic stem cell support is may be medically necessary to treat AML relapsing after prior therapy with high-dose chemotherapy and autologous stem cell support." 10/27/2005: Code Reference section updated; CPT-4 code 38230 added; ICD-9 Procedure 41.01, 41.02, 41.03, 41.09 added; HCPCS G0355, G0356, G0357, G0358, G0359, G0360, G0361, G0362, G0363, G0364 added, J9000-J9999 deleted 3/22/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/18/2007: Policy reviewed, no changes 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 7/14/2008: Policy updated; terminology modified but materially unchanged. High dose chemotherapy terminology removed from title and policy statement and replaced with stem cell transplantation (SCT).
G0363	IRRIG IMPLANTED VENOUS ACESS DEVICE DRUG DEL SYS	HCPCS	The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.26 per approval by Medical Policy Advisory Committee (MPAC) 7/13/2004: Code Reference section completed 7/1/2004: Reviewed by MPAC; The following changed from investigational to medically necessary: "High-dose chemotherapy with allogeneic stem cell support is may be medically necessary to treat AML relapsing after prior therapy with high-dose chemotherapy and autologous stem cell support." 10/27/2005: Code Reference section updated; CPT-4 code 38230 added; ICD-9 Procedure 41.01, 41.02, 41.03, 41.09 added; HCPCS G0355, G0356, G0357, G0358, G0359, G0360, G0361, G0362, G0363, G0364 added, J9000-J9999 deleted 3/22/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/18/2007: Policy reviewed, no changes 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 7/14/2008: Policy updated; terminology modified but materially unchanged. High dose chemotherapy terminology removed from title and policy statement and replaced with stem cell transplantation (SCT).
J9000	INJECTION, DOXORUBICIN HYDROCHLORIDE, 10 MG	HCPCS	The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.26 per approval by Medical Policy Advisory Committee (MPAC) 7/13/2004: Code Reference section completed 7/1/2004: Reviewed by MPAC; The following changed from investigational to medically necessary: "High-dose chemotherapy with allogeneic stem cell support is may be medically necessary to treat AML relapsing after prior therapy with high-dose chemotherapy and autologous stem cell support." 10/27/2005: Code Reference section updated; CPT-4 code 38230 added; ICD-9 Procedure 41.01, 41.02, 41.03, 41.09 added; HCPCS G0355, G0356, G0357, G0358, G0359, G0360, G0361, G0362, G0363, G0364 added, J9000-J9999 deleted 3/22/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/18/2007: Policy reviewed, no changes 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 7/14/2008: Policy updated; terminology modified but materially unchanged. High dose chemotherapy terminology removed from title and policy statement and replaced with stem cell transplantation (SCT).
G0364	HC BONE MARROW ASPIRATE & BIOPSY	HCPCS	The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.26 per approval by Medical Policy Advisory Committee (MPAC) 7/13/2004: Code Reference section completed 7/1/2004: Reviewed by MPAC; The following changed from investigational to medically necessary: "High-dose chemotherapy with allogeneic stem cell support is may be medically necessary to treat AML relapsing after prior therapy with high-dose chemotherapy and autologous stem cell support." 10/27/2005: Code Reference section updated; CPT-4 code 38230 added; ICD-9 Procedure 41.01, 41.02, 41.03, 41.09 added; HCPCS G0355, G0356, G0357, G0358, G0359, G0360, G0361, G0362, G0363, G0364 added, J9000-J9999 deleted 3/22/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/18/2007: Policy reviewed, no changes 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 7/14/2008: Policy updated; terminology modified but materially unchanged. High dose chemotherapy terminology removed from title and policy statement and replaced with stem cell transplantation (SCT).
G0362	Each add sequential infusion	HCPCS	The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY3/25/2004: See policy "High-Dose Chemotherapy with Hematopoietic Stem Cell Support for Malignancies" prior to 3/25/2004, separate policy developed and aligned with BCBSA policy # 8.01.26 per approval by Medical Policy Advisory Committee (MPAC) 7/13/2004: Code Reference section completed 7/1/2004: Reviewed by MPAC; The following changed from investigational to medically necessary: "High-dose chemotherapy with allogeneic stem cell support is may be medically necessary to treat AML relapsing after prior therapy with high-dose chemotherapy and autologous stem cell support." 10/27/2005: Code Reference section updated; CPT-4 code 38230 added; ICD-9 Procedure 41.01, 41.02, 41.03, 41.09 added; HCPCS G0355, G0356, G0357, G0358, G0359, G0360, G0361, G0362, G0363, G0364 added, J9000-J9999 deleted 3/22/2006: Coding updated. CPT4/HCPCS revisions added to policy 5/18/2007: Policy reviewed, no changes 12/20/2007: Coding updated per 2008 CPT/HCPCS revisions 7/14/2008: Policy updated; terminology modified but materially unchanged. High dose chemotherapy terminology removed from title and policy statement and replaced with stem cell transplantation (SCT).

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.